TeraRecon Cardiac.Chambers.MR (1.0.0)

The TeraRecon Cardiac.Chambers.MR system is designed to automatically segment cardiac chambers from MR scans to assist healthcare professionals in diagnosis and treatment planning. It leverages supervised deep learning algorithms to detect heart location and segment LV and RV myocardium, demonstrating high accuracy in non-clinical retrospective testing.

TeraRecon, Inc. has developed the TeraRecon Cardiac.Chambers.MR (1.0.0) system, a medical image processing software designed to automatically segment cardiac chambers. This system is intended for use with contrast or non-contrast MR scans of adult patients undergoing cardiac MR procedures, aiming to assist trained healthcare professionals in diagnosis or treatment planning. It works by detecting heart location and deriving left ventricular (LV) and right ventricular (RV) myocardium segmentation on DICOM-compliant cardiovascular MR images.The system utilizes supervised deep learning algorithms and comprises two components: one for Cine-ax images that segments both LV and RV myocardium, and another for De-ax images focusing on LV myocardium. Non-clinical testing involved a retrospective cohort study of 100 adult patients, where the device's output was compared against established ground truth data. The evaluation demonstrated that the TeraRecon Cardiac.Chambers.MR device met all predefined acceptance criteria, showing high accuracy in segmentation across different MR scanner manufacturers, patient demographics, and clinical conditions.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the system's performance vary with different levels of image quality or specific cardiac pathologies?; What specific metrics were used to define "high accuracy" in segmentation, and how do they compare to expert manual segmentation times and inter-observer variability?; Were there any specific patient populations or imaging protocols where the device showed reduced accuracy or limitations?; What is the potential impact of this automated segmentation on workflow efficiency and diagnostic confidence in a clinical setting?; Are there plans for prospective clinical validation studies or integration with other cardiovascular imaging modalities?